Alterity Therapeutics chairman reflects on two decades of progress as company enters new era

November 22, 2025 BioPharma

This is a preview of subscriber content

Subscribe now to continue reading.

Alterity Therapeutics (ASX:ATH) has marked a turning point in its corporate history, with longtime Chairman and company founder Geoffrey Kempler delivering his final address at the 2025 Annual General Meeting. …

Subscribe now to continue reading.

Latest Video

Health Department clarifies PBAC plan after confusion over paediatric access to biologics
December 10, 2025 - Latest News
If this was the plan, why wasn't it included in the response to questions last week?
December 10, 2025 - Latest News
Pfizer’s high-stakes sprint to build momentum in century-defining market
December 11, 2025 - Latest News
Opportunity cost is a moral and ethical question when it involves travel, tickets, or treating sick children
December 11, 2025 - Latest News
Mayne Pharma rejects Cosette’s attempt to terminate scheme deal
December 10, 2025 - Latest News

Alterity Therapeutics chairman reflects on two decades of progress as company enters new era

This is a preview of subscriber content

Latest Video

Most Read

Health Department clarifies PBAC plan after confusion over paediatric access to biologics

If this was the plan, why wasn't it included in the response to questions last week?

Pfizer’s high-stakes sprint to build momentum in century-defining market

Opportunity cost is a moral and ethical question when it involves travel, tickets, or treating sick children

Mayne Pharma rejects Cosette’s attempt to terminate scheme deal

New Stories

The 'Dispatched' Week in Review Podcast - 12 December

Medicines Australia gains a new voice with Vertex joining the association

BMS marks 70 years in Australia with renewed commitment to innovation and access

Opportunity cost is a moral and ethical question when it involves travel, tickets, or treating sick children

Pfizer’s high-stakes sprint to build momentum in century-defining market

Mayne Pharma rejects Cosette’s attempt to terminate scheme deal

TGA clears the way for LTR Pharma’s Phase 2 Study of SPONTAN

Sign In

Alterity Therapeutics chairman reflects on two decades of progress as company enters new era

This is a preview of subscriber content

Latest Video

Most Read

Health Department clarifies PBAC plan after confusion over paediatric access to biologics

If this was the plan, why wasn't it included in the response to questions last week?

Pfizer’s high-stakes sprint to build momentum in century-defining market

Opportunity cost is a moral and ethical question when it involves travel, tickets, or treating sick children

Mayne Pharma rejects Cosette’s attempt to terminate scheme deal

Follow Us

New Stories

The 'Dispatched' Week in Review Podcast - 12 December

Medicines Australia gains a new voice with Vertex joining the association

BMS marks 70 years in Australia with renewed commitment to innovation and access

Opportunity cost is a moral and ethical question when it involves travel, tickets, or treating sick children

Pfizer’s high-stakes sprint to build momentum in century-defining market

Mayne Pharma rejects Cosette’s attempt to terminate scheme deal

TGA clears the way for LTR Pharma’s Phase 2 Study of SPONTAN